2,445 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. purchased a new position in Repligen Co. (NASDAQ:RGEN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,445 shares of the biotechnology company’s stock, valued at approximately $308,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Repligen in the fourth quarter worth $48,208,000. Bank of New York Mellon Corp increased its holdings in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC lifted its stake in Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after purchasing an additional 199,322 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after purchasing an additional 121,305 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado grew its position in shares of Repligen by 448.0% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock valued at $20,293,000 after purchasing an additional 92,268 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Activity

In related news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on RGEN. Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Guggenheim began coverage on shares of Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $190.00 target price on shares of Repligen in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $188.38.

Repligen Stock Performance

Repligen stock opened at $140.43 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market capitalization of $7.85 billion, a P/E ratio of 561.72, a price-to-earnings-growth ratio of 4.14 and a beta of 0.94. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The company’s 50-day moving average is $147.66 and its 200 day moving average is $154.56.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same period in the prior year, the business posted $0.53 earnings per share. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Research analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.